Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms

NCT07102056 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT07102056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
December 31, 2027
Enrollment
152 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors